Ibodutant

From WikiMD.org
Jump to navigation Jump to search

Ibodutant

Ibodutant (pronounced as /ɪˈbɒdjuːtænt/) is a selective antagonist for the neurokinin 1 receptor. It is currently under development for the treatment of irritable bowel syndrome (IBS) and other related gastrointestinal disorders.

Etymology

The term "Ibodutant" is a coined name for this specific drug. The prefix "Ibo-" is derived from its chemical structure, while "-dutant" is a common suffix for drugs that act as antagonists.

Pharmacology

Ibodutant works by blocking the neurokinin 1 (NK1) receptor, a protein that plays a key role in the transmission of pain signals in the body. By inhibiting this receptor, Ibodutant can potentially alleviate the symptoms of conditions like IBS, which are often characterized by chronic abdominal pain and discomfort.

Clinical Trials

Several clinical trials have been conducted to evaluate the safety and efficacy of Ibodutant in patients with IBS. The results of these trials have shown promising results, with patients reporting significant improvements in their symptoms. However, further research is needed to fully understand the long-term effects of this drug.

Related Terms

External links

Esculaap.svg

This WikiMD dictionary article is a stub. You can help make it a full article.


Languages: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski